Advances in chemotherapy and immunopharmacology have transformed the management of infectious diseases, cancer, and immune-related disorders. Unit 4 focuses on the chemotherapy of urinary tract infections, sexually transmitted diseases, and malignancies, alongside emerging immunological therapies such as immunostimulants, immunosuppressants, protein drugs, monoclonal antibodies, and biosimilars. This news-style article presents a structured overview of these critical therapeutic areas shaping modern medicine.
Download UNIT 4 – Chemotherapy and Immunopharmacology Notes
Get simplified revision notes for this unit:
⬇️
Download Unit 4 Notes PDF
Chemotherapy of Urinary Tract Infections and Sexually Transmitted Diseases
Urinary Tract Infections: Therapeutic Approach
Urinary tract infections (UTIs) are among the most common bacterial infections, affecting individuals across all age groups. They are primarily caused by Escherichia coli and other gram-negative organisms. Chemotherapy of UTIs aims to eradicate pathogens while achieving high drug concentrations in urine.
Drugs such as fluoroquinolones, beta-lactams, nitrofurantoin, and cotrimoxazole are commonly used, depending on severity and resistance patterns. The choice of agent depends on microbial sensitivity, patient renal function, and recurrence risk. Short-course therapy is often sufficient for uncomplicated UTIs, while complicated infections require prolonged treatment.
Sexually Transmitted Diseases: Targeted Chemotherapy
Sexually transmitted diseases (STDs) pose significant public health challenges due to transmission rates and social impact. Bacterial STDs like syphilis, gonorrhea, and chlamydia are treated using specific chemotherapeutic agents such as penicillins, cephalosporins, macrolides, and tetracyclines.
Antiviral drugs are essential for managing viral STDs such as HIV and genital herpes. Combination therapy, patient compliance, and partner treatment are key components of effective STD chemotherapy, helping reduce resistance and prevent reinfection.
Chemotherapy of Malignancy: Targeting Uncontrolled Cell Growth
Principles of Cancer Chemotherapy
Chemotherapy of malignancy focuses on destroying rapidly dividing cancer cells while minimizing damage to normal tissues. Anticancer drugs act by interfering with DNA synthesis, mitosis, or essential metabolic pathways. However, because cancer cells share similarities with normal cells, toxicity remains a major challenge.
Major Classes of Anticancer Drugs
Alkylating agents damage DNA strands, preventing cell replication. Antimetabolites mimic normal cellular substrates, disrupting nucleic acid synthesis. Antitumor antibiotics interfere with DNA and RNA synthesis, while plant-derived alkaloids inhibit mitotic spindle formation.
Combination chemotherapy is widely practiced to enhance efficacy, reduce resistance, and allow lower doses of individual drugs. Supportive care is crucial to manage adverse effects such as immunosuppression, nausea, and organ toxicity.
Immunopharmacology: Modulating the Body’s Defense System
Introduction to Immunopharmacology
Immunopharmacology studies drugs that modify immune responses. These agents are essential in treating autoimmune diseases, preventing transplant rejection, enhancing immunity in immunocompromised patients, and managing inflammatory disorders.
Immunostimulants: Enhancing Immune Function
Role and Applications
Immunostimulants enhance the body’s natural defense mechanisms by stimulating immune cell activity. They are used in immunodeficiency states, chronic infections, and cancer therapy.
Examples include vaccines, cytokines, and colony-stimulating factors that increase white blood cell production. These agents improve resistance to infections and support recovery during chemotherapy-induced immunosuppression.
Immunosuppressants: Controlling Excessive Immune Responses
Clinical Importance
Immunosuppressants reduce immune activity and are essential in preventing organ transplant rejection and treating autoimmune diseases such as rheumatoid arthritis and lupus.
Drugs like corticosteroids, calcineurin inhibitors, and antiproliferative agents suppress immune cell activation and cytokine production. While effective, these drugs increase susceptibility to infections, requiring careful dose monitoring and patient education.
Protein Drugs: Precision Therapy Through Biotechnology
Nature and Therapeutic Value
Protein drugs are large biological molecules produced using recombinant DNA technology. They include insulin, growth hormones, clotting factors, and enzymes.
These drugs offer high specificity and potency but require parenteral administration and careful storage due to instability. Their introduction has revolutionized the treatment of diabetes, hormonal disorders, and genetic deficiencies.
Monoclonal Antibodies: Target-Specific Therapeutics
Mechanism and Applications
Monoclonal antibodies are engineered proteins designed to bind specific antigens. They target cancer cells, inflammatory mediators, or infectious agents with high precision.
In oncology, monoclonal antibodies block growth signals or mark cancer cells for immune destruction. In autoimmune diseases, they neutralize cytokines responsible for inflammation. Their specificity reduces off-target toxicity compared to traditional chemotherapy.
Targeted Drug Delivery to Antigens
Concept and Advantages
Targeted drug delivery systems link therapeutic agents to antibodies or ligands that recognize specific antigens. This approach concentrates drugs at disease sites while sparing healthy tissues.
Such strategies improve therapeutic index, reduce systemic toxicity, and enhance treatment outcomes, especially in cancer chemotherapy and immunotherapy.
Biosimilars: Expanding Access to Biologic Therapies
Definition and Significance
Biosimilars are biologic products highly similar to already approved reference biologics. They offer comparable safety, efficacy, and quality at a lower cost.
Biosimilars improve patient access to advanced therapies, particularly in chronic diseases requiring long-term treatment. Regulatory approval ensures rigorous evaluation of similarity without unnecessary duplication of clinical trials.